Bone SPECT-based segmented attenuation correction for quantitative analysis of bone metastasis (B-SAC): comparison with CT-based attenuation correction.
Bone
Bone SPECT
Quantitation
SPECT
SPECT/CT
SUV
Segmentation
Segmented attenuation correction
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
19 Mar 2019
19 Mar 2019
Historique:
received:
26
12
2018
accepted:
12
03
2019
entrez:
20
3
2019
pubmed:
20
3
2019
medline:
20
3
2019
Statut:
epublish
Résumé
Evidence has shown the clinical usefulness of measuring the metastatic tumor burden of bone for prognostic assessment especially in prostate cancer; quantitative evaluation by dedicated SPECT is difficult due to the lack of attenuation correction (AC) method. We developed a novel method for attenuation correction using bone SPECT emission data (bone SPECT-based segmented attenuation correction; B-SAC) where emission data were virtually segmented into three tissues (i.e., bone, soft tissue, and air). Then, the pixel values in SPECT were replaced by 50 for the virtual soft tissue, and - 1000 for the virtual air. The replaced pixel values for the virtual bone were based on the averaged CT values of the normal vertebrae (B-SAC The SUVs in the five reconstruction conditions were all correlated with those in CTAC(+)SC(+)RR(+) (p < 0.01), and the correlations between B-SAC The results of this preliminary study suggest the potential for B-SAC to improve the quantitation of bone metastases in bone SPECT when X-ray CT or transmission CT data are not available. Considering the small but unignorable differences of lesional SUVs between CTAC and B-SAC, SUVs obtained with the current version of B-SAC seem difficult to be directly compared with those obtained with CTAC.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence has shown the clinical usefulness of measuring the metastatic tumor burden of bone for prognostic assessment especially in prostate cancer; quantitative evaluation by dedicated SPECT is difficult due to the lack of attenuation correction (AC) method. We developed a novel method for attenuation correction using bone SPECT emission data (bone SPECT-based segmented attenuation correction; B-SAC) where emission data were virtually segmented into three tissues (i.e., bone, soft tissue, and air). Then, the pixel values in SPECT were replaced by 50 for the virtual soft tissue, and - 1000 for the virtual air. The replaced pixel values for the virtual bone were based on the averaged CT values of the normal vertebrae (B-SAC
RESULTS
RESULTS
The SUVs in the five reconstruction conditions were all correlated with those in CTAC(+)SC(+)RR(+) (p < 0.01), and the correlations between B-SAC
CONCLUSIONS
CONCLUSIONS
The results of this preliminary study suggest the potential for B-SAC to improve the quantitation of bone metastases in bone SPECT when X-ray CT or transmission CT data are not available. Considering the small but unignorable differences of lesional SUVs between CTAC and B-SAC, SUVs obtained with the current version of B-SAC seem difficult to be directly compared with those obtained with CTAC.
Identifiants
pubmed: 30888521
doi: 10.1186/s13550-019-0501-1
pii: 10.1186/s13550-019-0501-1
pmc: PMC6424988
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27Subventions
Organisme : Nihon Medi-Physics Co., Ltd.
ID : none
Organisme : Nihon Medi-Physics Co., Ltd.
ID : none
Références
Clin Nucl Med. 1999 Jun;24(6):407-13
pubmed: 10361935
Eur J Nucl Med. 2001 Feb;28(2):155-64
pubmed: 11303885
Eur J Nucl Med. 2001 Sep;28(9):1326-35
pubmed: 11585291
Ann Nucl Med. 2004 Apr;18(2):137-43
pubmed: 15195761
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1335-41
pubmed: 19289263
Ann Nucl Med. 2009 Jul;23(5):501-6
pubmed: 19412655
J Nucl Med. 1991 Jan;32(1):161-5
pubmed: 1988625
J Nucl Med. 2010 Jun;51(6):921-8
pubmed: 20484423
Nuklearmedizin. 2011;50(4):141-6
pubmed: 21594304
Phys Med Biol. 2011 Jul 21;56(14):4613-29
pubmed: 21725141
J Clin Oncol. 2012 Feb 10;30(5):519-24
pubmed: 22231045
J Nucl Med. 2012 May;53(5):709-15
pubmed: 22492732
EJNMMI Res. 2012 Aug 27;2(1):45
pubmed: 22925467
Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S104-14
pubmed: 24554052
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1113-22
pubmed: 24570094
PET Clin. 2014 Jul;9(3):287-97
pubmed: 25030392
J Nucl Med. 2015 Jul;56(7):1067-74
pubmed: 25952739
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1723-38
pubmed: 27262701
EJNMMI Res. 2017 Dec;7(1):53
pubmed: 28639254
Ann Nucl Med. 2018 Feb;32(2):105-113
pubmed: 29243019
JAMA Oncol. 2018 Jul 1;4(7):944-951
pubmed: 29799999
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464